12 completed, 7 terminated, 1 active not recruiting, 1 withdrawn. 21 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 21 | Completed 12, Terminated 7, Active not recruiting 1, Withdrawn 1 |
| Phase 2 | 6 | Completed 3, Terminated 2, Withdrawn 1 |
Follow Testicular Lymphoma: new trials by email Literature Review of Testicular Lymphoma trials Research Report on Testicular Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma rituximab, lenalidomide, romidepsin - B-cell Adult Acute Lymphoblastic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Phase 1 / Phase 2 | Withdrawn | Mayo Clinic | 2016-10-01 | 2016-08-11 | |
| CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma 6,8-bis(benzylthio)octanoic acid, bendamustine hydrochloride, rituximab - B-cell Adult Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia | Phase 1 | Terminated | Wake Forest University Health Sciences | 1 | 2014-12-01 | 2018-07-02 |
| Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection Ibrutinib, Laboratory Biomarker Analysis, Pharmacological Study - Adult B Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 72 | 2014-09-01 | 2015-08-20 |
| Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas lenalidomide, etoposide, prednisone - Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | University of Chicago | 55 | 2014-07-29 | 2026-03-11 |
| MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma anti-endosialin/TEM1 monoclonal antibody MORAb-004, pharmacological study, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Completed | Morphotek | 27 | 2013-11-01 | 2016-01-08 |
| Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells, autologous hematopoietic stem cell transplantation, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Cutaneous B-cell Non-Hodgkin Lymphoma | Phase 1 | Active not recruiting | City of Hope Medical Center | 30 | 2013-10-08 | 2026-06-25 |
| Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas brentuximab vedotin, rituximab, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 / Phase 2 | Terminated | Northwestern University | 20 | 2013-03-05 | 2021-09-01 |
| Ipilimumab and Local Radiation for Selected Solid Tumors Ipilimumab, Radiation therapy - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Terminated | Stanford University | 3 | 2013-02-01 | 2024-01-24 |
| Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma Alisertib, Laboratory Biomarker Analysis, Pharmacological Study - Adult B Acute Lymphoblastic Leukemia, Adult T Acute Lymphoblastic Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 34 | 2012-04-16 | 2018-04-11 |
| Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Bendamustine Hydrochloride, Pharmacological Study, Rituximab - Adult B Acute Lymphoblastic Leukemia, Adult Nasal Type Extranodal NK/T-Cell Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 43 | 2011-07-01 | 2019-12-16 |
| Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies fludarabine phosphate, methoxyamine, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Completed | Case Comprehensive Cancer Center | 20 | 2011-05-01 | 2015-08-13 |
| Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers Laboratory Biomarker Analysis, Lenalidomide, Pharmacological Study - Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 | Phase 1 | Completed | National Cancer Institute (NCI) | 17 | 2010-11-24 | 2017-09-25 |
| AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma Pharmacodynamic Studies, Fatigue Inventory, Pharmacogenomic studies - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Completed | Amir Mortazavi | 44 | 2010-05-04 | 2018-06-04 |
| Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma lenalidomide, vorinostat, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Terminated | City of Hope Medical Center | 30 | 2010-05-01 | 2010-12-09 |
| Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy sunitinib malate, pharmacological study, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Phase 1 | Completed | National Cancer Institute (NCI) | 42 | 2009-08-01 | 2014-03-17 |
| Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery Dasatinib, Pharmacological Study - Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 80 | 2008-10-01 | 2015-07-02 |
| Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma DI-Leu16-IL2 immunocytokine, rituximab, flow cytometry - Anaplastic Large Cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma | Phase 1 | Completed | City of Hope Medical Center | 9 | 2008-03-17 | 2026-10-23 |
| Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma bevacizumab, cediranib maleate - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 57 | 2007-05-01 | 2014-02-19 |
| MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma ipilimumab, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 18 | 2004-06-01 | 2014-05-30 |
| Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer total-body irradiation, fludarabine phosphate, cyclosporine - Acute Undifferentiated Leukemia, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 21 | 2000-05-01 | 2020-01-21 |
Showing 20 of 21. Sign in to see all of them.
Intraocular Lymphoma (21) · Lymphoma, B-Cell, Marginal Zone (21) · Lymphoma, Follicular (21) · Lymphoma, Non-Hodgkin (21) · Waldenstrom Macroglobulinemia (21) · Lymphoma, Large-Cell, Immunoblastic (20) · Lymphoma, Mantle-Cell (20) · Burkitt Lymphoma (19) · Leukemia, Lymphocytic, Chronic, B-Cell (19) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (19) · Lymphoma, Large B-Cell, Diffuse (18) · Leukemia, Hairy Cell (16) · Lymphoma, Large-Cell, Anaplastic (15) · Mycosis Fungoides (15) · Sezary Syndrome (15)
Blood Protein Disorders (21) · Cardiovascular Diseases (21) · Eye Neoplasms (21) · Hematologic Diseases (21) · Hemic and Lymphatic Diseases (21) · Hemorrhagic Disorders (21) · Hemostatic Disorders (21) · Immune System Diseases (21) · Immunoproliferative Disorders (21) · Lymphatic Diseases (21) · Lymphoma (21) · Lymphoma, B-Cell (21) · Lymphoproliferative Disorders (21) · Neoplasms (21) · Neoplasms by Histologic Type (21)
Rituximab (6) · Lenalidomide (4) · Bendamustine Hydrochloride (2) · CTLA-4 Antigen (2) · Ipilimumab (2) · Peripheral Blood Stem Cell Transplantation (2) · Vorinostat (2) · fludarabine phosphate (2) · Bevacizumab (1) · Blotting, Western (1) · Brentuximab Vedotin (1) · Cyclophosphamide (1) · Cyclosporine (1) · Dasatinib (1) · Doxorubicin (1)
National Cancer Institute (NCI) (8) · City of Hope Medical Center (3) · Fred Hutchinson Cancer Center (2) · Amir Mortazavi (1) · Case Comprehensive Cancer Center (1) · Mayo Clinic (1) · Morphotek (1) · Northwestern University (1) · Stanford University (1) · University of Chicago (1) · Wake Forest University Health Sciences (1)
United States (20) · Italy (1)
Adam Petrich, MD (1) · Ajay Gopal (1) · Amir Mortazavi, MD (1) · David Hong (1) · David Maloney (1) · Elizabeth Budde (1) · George A. Fisher, MD, PhD (1) · Grzegorz Nowakowski (1) · John Deeken (1) · John Gerecitano (1) · John Sarantopoulos (1) · Leslie Andritsos (1) · Leslie Popplewell (1) · Paolo Caimi, MD (1) · Robin Norris (1)
PMID 22259028, PMID 24474568, PMID 26943915, PMID 27118452, PMID 28270022, PMID 28314788, PMID 29292843, PMID 31617432, PMID 32499241, PMID 33492438, PMID 34515338, PMID 40720747
P30CA015083 (2), P30CA015704 (2), P30CA016058 (2), P50CA107399 (2), U01CA121947 (2), P01CA044991 (1), P01CA078902 (1), P30CA008748 (1), P30CA012197 (1), P30CA014599 (1), P30CA016672 (1), P30CA033572 (1), U01CA062461 (1), U01CA062505 (1), U01CA069856 (1)